Advertisement

Topics

Mitochon Pharmaceuticals Announces First Patent Allowance for Mitochondrial Targeted Therapies for Neurodegeneration

10:00 EST 8 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Mitochon Pharmaceuticals today announced that it was notified by the US Patent and Trade Mark Office of allowance on its first patent, US 15/002,531 “INDUCED EXPRESSION OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) FOR TR...

Other Sources for this Article

Mitochon Pharmaceuticals, Inc.
Robert Alonso, President & CEO
215-313-3905
ralonso@mitochonpharma.com

NEXT ARTICLE

More From BioPortfolio on "Mitochon Pharmaceuticals Announces First Patent Allowance for Mitochondrial Targeted Therapies for Neurodegeneration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Huntington's Disease
Huntington's disease is a hereditary disease caused by a defect in a single gene on Chromosome 4 that is inherited in an autosomal dominant fashion. The defect causes a part of DNA, called a CAG repeat, to occur many more times than it is supposed to...